BOSTON and SAN DIEGO, April 30, 2026 /PRNewswire/ — Brenig Therapeutics Inc. (Brenig), a clinical-stage biotechnology company advancing best-in-class therapies for neurodegenerative, neuroinflammatory, and cardiometabolic diseases, today announced that Alexei Pushechnikov, PhD, will…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
